We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

0001193125-15-329662 Sample Contracts

CYTOMX THERAPEUTICS, INC. (a Delaware corporation) Shares of Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • September 28th, 2015 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • New York
Sample 1Sample 2Sample 3See All (932)

Standard Contracts

Free NDA TemplateoneNDA-badgeFree SaaS TemplateoneSaaS-badge
COLLABORATION AND LICENSE AGREEMENT
Collaboration and License Agreement • September 28th, 2015 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • Delaware

THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of May 23, 2014 (the “Execution Date”) by and between CYTOMX THERAPEUTICS, INC., a corporation organized under the laws of the State of Delaware, having its principal place of business at 343 Oyster Point Blvd., Suite 100, South San Francisco, CA, 94080-1913 (“CytomX”), and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York, USA 10154 (“BMS”). CytomX and BMS are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

Sample 1Sample 2Sample 3See All (5)
RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT BY AND BETWEEN PFIZER INC. AND CYTOMX THERAPEUTICS, INC. MAY 30, 2013
Research Collaboration, Option and License Agreement • September 28th, 2015 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • Delaware

This Research Collaboration, Option and License Agreement (the “Agreement”) is entered into as of May 30, 2013 (the “Effective Date”), by and among Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 235 East 42nd Street, New York, New York, 10017 United States (“Pfizer”) and CytomX Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a place of business at 650 Gateway Blvd., Suite 125, South San Francisco, California, 94080 United States (“CytomX”). Pfizer and CytomX may each be referred to herein individually as a “Party” and collectively as the “Parties.”

Sample 1Sample 2Sample 3See All (4)
RESEARCH COLLABORATION AGREEMENT BETWEEN CYTOMX THERAPEUTICS, INC. AND IMMUNOGEN, INC. JANUARY 8, 2014
Research Collaboration Agreement • September 28th, 2015 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • New York

This Research Collaboration and License Agreement (the “Agreement”) is entered into as of 1 (the “Effective Date”), by and between CytomX Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a place of business at 343 Oyster Point Blvd., Suite 100, South San Francisco, California, 94080 United States (“CytomX”) and ImmunoGen, Inc., a corporation organized and existing under the laws of Massachusetts and having a place of business at 830 Winter Street, Waltham, Massachusetts, 02451 (“ImmunoGen”). CytomX and ImmunoGen may each be referred to herein individually as a “Party” and collectively as the “Parties.”

Sample 1Sample 2Sample 3See All (4)
SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS
Separation Agreement • September 28th, 2015 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • California

This Separation and Release Agreement (“Agreement”) is made this 30th day of September, 2014 by and between Henry B. Lowman, Ph.D. (“Executive”) and CytomX Therapeutics, Inc. (“Company”).

Sample 1